NCT00826033已完成不适用
Fluorine-18-α-Methyltyrosine Positron Emission Tomography to Measure Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for positron emission tomography (PET). The investigators evaluated the value of 18F-FMT PET for the assessment of therapy response in patients with lung cancer as compared with that of 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) PET.
The patients with lung cancer underwent PET studies with 18F-FDG and 18F-FMT before and after radio-/chemotherapy. The investigators used the ratio of the SUVmax of the mediastinal (N2) lymph node to the SUVmax of the primary tumor (N/P ratio ). All patients were divided into two groups of N/P ratio<1 and N/P ratio≥1, and the survival time was estimated by Kaplan-Meier method.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •primary lung cancer All patients received first-line chemotherapy
排除标准
- •Patients with diabetus mellitus
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Diagnostic Usefulness of Fluorine-18-α-Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis PatientSarcoidosisNCT00369980Gunma University
已完成
不适用
Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung CancerCarcinoma, Non-Small-Cell LungNCT00464282Gunma University
已完成
不适用
Evaluation of Thoracic Tumors With 18F-FMT and 18F-FDG PET-CT A Clinicopathological StudyNon-Small Cell Lung CancerNCT00698373Gunma University
已完成
不适用
18F-FET PET/CT in the Management of GliomaGliomaNCT06563024Buddhist Tzu Chi General Hospital36
进行中(未招募)
不适用
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerBrain and Central Nervous System TumorsChronic Myeloproliferative DisordersLymphoproliferative DisorderMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsUnspecified Adult Solid Tumor, Protocol SpecificLeukemiaLymphomaNCT00935090Barbara Ann Karmanos Cancer Institute80
